Agentix Corp.
Agentix develops pharmaceutical treatments for metabolic diseases, with a focus on two peripherally restricted cannabinoid type 1 receptor drug candidates intended to treat conditions including obesity, type 2 diabetes and fatty liver disease. Its pipeline includes AGTX-2004, which has FDA clearance for an Investigational New Drug application, and AGTX-2003, which is undergoing additional animal studies in preparation for an application. Agentix holds worldwide exclusive licenses for the candidates and aims to advance new chemical entities to initial clinical efficacy before partnering with larger biopharmaceutical companies for later development and commercialization. Agentix conducts development activities through its Australian subsidiary, Agentix Australia Pty Ltd. It has no full-time or part-time employees, and its business is operated by one of its two directors. Its executive offices are in Dana Point, California.
No SEC Form 4 filings for $AGTX in the last 30 days.
See all $AGTX insider activity →Agentix reported no revenue for 3Q 2026, with a net loss of $91.03K, narrower than the prior year's $144.11K loss. Professional fees and R&D expenses decreased, while general and administrative expenses remained unchanged. Diluted EPS was $0.00.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AGTX (Agentix Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
The filing reveals a narrowed loss but still negative earnings, indicating limited upside.
AlphAI scores every news story that mentions AGTX with an AI model for sentiment and relevance, and aggregates insider trades from Agentix Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Agentix reported no revenue for 3Q 2026, with a net loss of $91.03K, narrower than the prior year's $144.11K loss. Professional fees and R&D expenses decreased, while general and administrative expenses remained unchanged. Diluted EPS was $0.00.
